Validation of Viral Inactivation Protocols for Therapeutic Blood Products against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

Therapeutic blood products including convalescent plasma/serum and immunoglobulins concentrated from convalescent plasma, such as intravenous immunoglobulins or hyperimmune globulins, and monoclonal antibodies are passive immunotherapy options for novel coronavirus disease 2019 (COVID-19). They have...

Descripción completa

Detalles Bibliográficos
Autores principales: Belem, Wendimi Fatimata, Liu, Ching-Hsuan, Hu, Yee-Tung, Burnouf, Thierry, Lin, Liang-Tzung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698982/
https://www.ncbi.nlm.nih.gov/pubmed/36366517
http://dx.doi.org/10.3390/v14112419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698982/
https://www.ncbi.nlm.nih.gov/pubmed/36366517
http://dx.doi.org/10.3390/v14112419

Ejemplares similares